tranexamic acid and Complications, Hematologic Pregnancy studies

Research Excerpts

Excerpt	Relevance	Reference
"The aim of this study is critically to review the available evidence regarding the use, efficacy and safety of tranexamic acid in the management of hemorrhage during pregnancy and for prevention and treatment of postpartum hemorrhage."	8.87	Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. ( Kadir, RA; Peitsidis, P, 2011)
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e."	7.68	Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993)
" The highest-quality evidence is for the use of tranexamic acid in postpartum hemorrhage, which has been shown to decrease bleeding-related mortality in women without bleeding disorders."	4.98	Inherited Bleeding Disorders in the Obstetric Patient. ( Bannow, BS; Konkle, BA, 2018)
"The aim of this study is critically to review the available evidence regarding the use, efficacy and safety of tranexamic acid in the management of hemorrhage during pregnancy and for prevention and treatment of postpartum hemorrhage."	4.87	Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. ( Kadir, RA; Peitsidis, P, 2011)
" In postpartal period an excellent control of bleeding was obtained by regularly administering FVIII concentrate for several days as well by concomitant use of tranexamic acid and oral contraceptive pills in the next 6 weeks."	3.85	Pregnancy and delivery in a woman with severe haemophilia A. ( Antic, DA; Bodrozic, JN; Djunic, IS; Lekovic, DR; Miljic, PS; Mitrovic, MM; Petronijevic, MA; Petronijevic-Vrzic, SM, 2017)
"In cases of placental abruption complicated with disseminated intravascular coagulation, intrapartum administration of coagulation factors can simultaneously promote effective labor and correct hypofibrinogenemia, enabling minimally invasive vaginal delivery."	3.80	Intrapartum anti-disseminated intravascular coagulation therapy leading to successful vaginal delivery following intrauterine fetal death caused by placental abruption: a case report. ( Baba, K; Era, S; Honda, M; Matsunaga, S; Seki, H; Takai, Y, 2014)
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e."	3.68	Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993)
"Neonatal bleeding was described in 6 affected male neonates, mostly after instrumental delivery or emergency CS, but insufficient information was provided to reliably investigate neonatal outcome in relation to management."	2.72	Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. ( Bloemenkamp, KWM; Driessens, MHE; Duvekot, JJ; Eikenboom, J; Kruip, MJHA; Lely, AT; Makelburg, ABU; Mauser-Bunschoten, EP; Middeldorp, JM; Nieuwenhuizen, L; Peters, M; Punt, MC; Schutgens, REG; van Galen, KPM; Waning, ML, 2021)
"Perioperative prophylactic treatment for high-bleeding-risk surgery in patients with severe FXI deficiency is based on fresh frozen plasma (FFP) transfusions or FXI concentrate (where available)."	1.91	[PERIOPERATIVE MANAGEMENT OF AN ADOLESCENT GIRL WITH SEVERE FACTOR XI DEFICIENCY AND INHIBITORS]. ( Berger-Achituv, S; Keren-Politansky, A; Mandel-Shorer, N; Oren-Malek, L; Revel-Vilk, S, 2023)
"The delivery was complicated by postpartum hemorrhage, which resolved with the addition of uterotonic agents."	1.43	Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report. ( Andrews, J; Dolan, S; Matei, A; Rivard, GÉ, 2016)
"Glanzmann's thrombasthenia is a congenitally acquired platelet disorder with an autosomal recessive mode of inheritance."	1.33	Pregnancy in a patient of Glanzmann's thrombasthenia. ( Chanana, C; Deka, D; Malhotra, N, 2006)

Research

Studies (23)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Centralized Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (8.70)	18.7374
1990's	1 (4.35)	18.2507
2000's	6 (26.09)	29.6817
2010's	10 (43.48)	24.3611
2020's	4 (17.39)	2.80

Authors	Studies
Mandel-Shorer, N	1
Oren-Malek, L	1
Keren-Politansky, A	1
Berger-Achituv, S	1
Revel-Vilk, S	1
Benhamou, D	1
Keita, H	1
Ducloy-Bouthors, AS	1
Kinsey, KE	1
Ganz, E	1
Khalil, S	1
Brustman, L	1
Punt, MC	1
Waning, ML	1
Mauser-Bunschoten, EP	1
Kruip, MJHA	1
Eikenboom, J	1
Nieuwenhuizen, L	1
Makelburg, ABU	1
Driessens, MHE	1
Duvekot, JJ	1
Peters, M	1
Middeldorp, JM	1
Bloemenkamp, KWM	1
Schutgens, REG	1
Lely, AT	1
van Galen, KPM	1
Patil, V	1
Ratnayake, G	1
Fastovets, G	1
Verghese, L	1
Tingi, E	1
Thachil, J	1
Hay, C	1
Byrd, L	1
Bannow, BS	1
Konkle, BA	1
Bistervels, IM	1
Scheres, LJJ	1
Hamulyák, EN	1
Middeldorp, S	1
Honda, M	1
Matsunaga, S	1
Era, S	1
Takai, Y	1
Baba, K	1
Seki, H	1
Matei, A	1
Dolan, S	1
Andrews, J	1
Rivard, GÉ	1
Bodrozic, JN	1
Miljic, PS	1
Lekovic, DR	1
Petronijevic, MA	1
Antic, DA	1
Mitrovic, MM	1
Petronijevic-Vrzic, SM	1
Djunic, IS	1
Chi, C	1
Kulkarni, A	1
Lee, CA	1
Kadir, RA	2
Peitsidis, P	1
Domschke, C	1
Strowitzki, T	1
Huth-Kuehne, A	1
Staritz, P	1
Sohn, C	1
Schuetz, F	1
Martín-Salces, M	1
Jiménez-Yuste, V	1
Álvarez-Román, MT	1
Rivas-Pollmar, I	1
Rodríguez de la Rúa, A	1
Mannucci, PM	1
González González, G	1
Rodríguez Agea, E	1
Ruiz Zafra, V	1
Kopeć, I	1
Maślanko, K	1
Litmanowicz, M	1
Stefańska, E	1
Mikos, A	1
Warzocha, K	1
Malhotra, N	1
Chanana, C	1
Deka, D	1
Prabu, P	1
Parapia, LA	1
Lindoff, C	1
Rybo, G	1
Astedt, B	1
Storm, O	1
Weber, J	1
Schulman, S	1
Johnsson, H	1
Egberg, N	1
Blombäck, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial[NCT02302456]	Phase 3	4,079 participants (Actual)	Interventional	2015-02-28	Completed
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211]	Phase 2	30 participants (Anticipated)	Interventional	2022-07-12	Recruiting
National Study of Moderate and Severe Von Willebrand Disease in the Netherlands[NCT00510042]		1,100 participants (Anticipated)	Observational	2007-07-31	Completed
Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458]		265 participants (Actual)	Observational	2012-11-05	Active, not recruiting
The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128]	Phase 4	50 participants (Anticipated)	Interventional	2021-08-01	Not yet recruiting
Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study[NCT00740116]	Phase 4	100 participants (Actual)	Interventional	2008-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

Centralized Factor VIII (FVIII) Antigen (FVIII:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Intervention	IU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)	1.63

Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Intervention	IU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)	3.64

Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

Centralized Von Willebrand Factor (VWF) Propeptide Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Intervention	IU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)	2.43

Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

Centralized Von Willebrand Factor Antigen (VWF:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Intervention	IU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)	7.3

Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

Local Laboratory Tests for Type 3 Von Willebrand's Disease (VWD3) Diagnosis (Composite)

Intervention	IU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)	1.29

"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)

Number of Patients With Available Local Laboratory Test for Anti-Von Willebrand Factor (Anti-VWF) Antibodies

Intervention	Participants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)	265

Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)

Patients Experiencing Allergic Reactions During Use of Von Willebrand Factor (VWF)-Containing Concentrates

Intervention	Participants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)	4

Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)

Number of Participants With Previous Use of Blood Products

Intervention	Participants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)	41

Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)

Median Number of Transfused Units of Red Blood Cells (RBC)

Intervention	Participants (Count of Participants)
	Packed red cells	Cryoprecipitates	Fresh frozen plasma	Platelet concentrates
Type 3 Von Willebrand's Disease (VWD3)	24	123	10	1

Median number of red blood cells transfused among those who received RBC transfusions (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Number of Patients Receiving Blood Transfusions

Intervention	units (Median)
The Placebo Group	2
The Tranexamic Acid Group	2

Total number of RBC-transfused women in each group (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Number of Patients With Clinically or Radiologically Verified Thromboembolic Events Within 5 Weeks Postoperatively

Intervention	participants (Number)
Tranexamic Group	15
Placebo Group	22

Thromboembolic events including arterial thrombosis, muscle vein thrombosis, superficial and deep venous thrombosis. (NCT00740116)
Timeframe: From time of operation to 5 weeks postoperatively.

Number of Units of Red Blood Cells (RBC) Transfused

Intervention	Participants (Count of Participants)
Tranexamic Group	2
Placebo Group	5

Total number of red blood cells (RBC) transfused across all participants (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Perioperative Bleeding Volume

Intervention	units (Number)
Tranexamic Group	38
Placebo Group	53

Estimation of total blood loss was based on the estimation of the Hb balance method (Brecher, et al.1997) with the assumption that the body blood volume was normalised on the fifth postoperative day. The haemoglobin level was assessed preoperatively and on the fifth postoperative day. The predicted blood volume (PBV, l) was calculated according to the method described by Nadler et al. (1962), using body weight and height. The extravasation of haemoglobin was calculated taking into account allogenic transfused haemoglobin. Total blood loss perioperatively was related to the patient's preoperative haemoglobin value. Blood loss due to haematomas or a reoperation within the first five days after surgery was also considered. (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Reviews

8 reviews available for tranexamic acid and Complications, Hematologic Pregnancy

Other Studies

15 other studies available for tranexamic acid and Complications, Hematologic Pregnancy

Article	Year
Coagulation changes and thromboembolic risk in COVID-19 obstetric patients. Anaesthesia, critical care & pain medicine, 2020, Volume: 39, Issue:3 Topics: Anticoagulants; Autoantibodies; Betacoronavirus; Blood Proteins; Cerebrovascular Disorders; Contrain	2020
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. Blood reviews, 2021, Volume: 49 Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Delivery, Obstetric; Female; Hemophilia A; Hemor	2021
Clinical 'pearls' of maternal critical care Part 2: sickle-cell disease in pregnancy. Current opinion in anaesthesiology, 2017, Volume: 30, Issue:3 Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Antifibrinolytic Agents; Blood Transfusion; Critical Care	2017
Management of parturients with Factor XI deficiency-10year case series and review of literature. European journal of obstetrics, gynecology, and reproductive biology, 2017, Volume: 215 Topics: Antifibrinolytic Agents; Delivery, Obstetric; Factor XI Deficiency; Female; Humans; Pregnancy; Pregn	2017
Inherited Bleeding Disorders in the Obstetric Patient. Transfusion medicine reviews, 2018, Volume: 32, Issue:4 Topics: Blood Coagulation; Deamino Arginine Vasopressin; Female; Fibrinolytic Agents; Hematology; Hemophilia	2018
Sex matters: Practice 5P's when treating young women with venous thromboembolism. Journal of thrombosis and haemostasis : JTH, 2019, Volume: 17, Issue:9 Topics: Adult; Anticoagulants; Contraceptives, Oral, Combined; Disease Susceptibility; Female; Heparin, Low-	2019
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4 Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage	2011
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4 Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage	2011
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4 Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage	2011
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:4 Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage	2011
Treatment of von Willebrand's Disease. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo	2004
Treatment of von Willebrand's Disease. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo	2004
Treatment of von Willebrand's Disease. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo	2004
Treatment of von Willebrand's Disease. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo	2004

Article	Year
[PERIOPERATIVE MANAGEMENT OF AN ADOLESCENT GIRL WITH SEVERE FACTOR XI DEFICIENCY AND INHIBITORS]. Harefuah, 2023, Volume: 162, Issue:1 Topics: Adolescent; Factor XI Deficiency; Female; Hemorrhage; Humans; Pregnancy; Pregnancy Complications, He	2023
Intraoperative coagulopathy during cesarean section as an unsuspected initial presentation of COVID-19: a case report. BMC pregnancy and childbirth, 2020, Aug-24, Volume: 20, Issue:1 Topics: Adult; Antifibrinolytic Agents; Betacoronavirus; Blood Coagulation Disorders; Blood Loss, Surgical;	2020
Intrapartum anti-disseminated intravascular coagulation therapy leading to successful vaginal delivery following intrauterine fetal death caused by placental abruption: a case report. Journal of medical case reports, 2014, Dec-23, Volume: 8 Topics: Abruptio Placentae; Adult; Antifibrinolytic Agents; Coagulants; Delivery, Obstetric; Disseminated In	2014
Management of Labour and Delivery in a Patient With Acquired Factor VII Deficiency With Inhibitor: A Case Report. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2016, Volume: 38, Issue:2 Topics: Adult; Factor VII Deficiency; Factor VIIa; Female; Hemostatics; Humans; Postpartum Hemorrhage; Pregn	2016
Pregnancy and delivery in a woman with severe haemophilia A. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2017, Volume: 28, Issue:6 Topics: Adult; Factor VIII; Female; Hemophilia A; Hemorrhage; Humans; Pregnancy; Pregnancy Complications, He	2017
The obstetric experience of women with factor XI deficiency. Acta obstetricia et gynecologica Scandinavica, 2009, Volume: 88, Issue:10 Topics: Adult; Antifibrinolytic Agents; Delivery, Obstetric; Factor XI; Factor XI Deficiency; Female; Humans	2009
Successful in vitro fertilization and pregnancy in Glanzmann thrombasthenia. Haemophilia : the official journal of the World Federation of Hemophilia, 2012, Volume: 18, Issue:5 Topics: Adult; Antifibrinolytic Agents; Cesarean Section; Female; Fertilization in Vitro; Humans; Infant, Ne	2012
Management of delivery with FVIII/VWF concentrates in a pregnant woman with type 3 von Willebrand disease and alloantibodies. Thrombosis and haemostasis, 2012, Volume: 108, Issue:4 Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cesarean Section; Factor VIII; Female; Humans; In	2012
[Antihemorrhagic prophylaxis in low risk surgery in Bernard-Soulier syndrome]. Revista espanola de anestesiologia y reanimacion, 2005, Volume: 52, Issue:9 Topics: Adult; Antifibrinolytic Agents; Bernard-Soulier Syndrome; Deamino Arginine Vasopressin; Female; Hemo	2005
[Bernard-Soulier syndrome during pregnancy: a case report]. Ginekologia polska, 2005, Volume: 76, Issue:10 Topics: Adult; Antigens, Human Platelet; Bernard-Soulier Syndrome; Deamino Arginine Vasopressin; Female; Hum	2005
Pregnancy in a patient of Glanzmann's thrombasthenia. Indian journal of medical sciences, 2006, Volume: 60, Issue:3 Topics: Adult; Antifibrinolytic Agents; Female; Humans; Patient Readmission; Platelet Transfusion; Postpartu	2006
Bernard-Soulier syndrome in pregnancy. Clinical and laboratory haematology, 2006, Volume: 28, Issue:3 Topics: Adolescent; Adult; Bernard-Soulier Syndrome; Blood Platelets; Consanguinity; Deamino Arginine Vasopr	2006
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2 Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P	1993
[Prolonged treatment with tranexamic acid (Cyclocapron) during pregnancy]. Ugeskrift for laeger, 1976, Jul-12, Volume: 138, Issue:29 Topics: Adult; Cyclohexanecarboxylic Acids; Female; Fibrinolysis; Humans; Pregnancy; Pregnancy Complications	1976
DDAVP-induced correction of prolonged bleeding time in patients with congenital platelet function defects. Thrombosis research, 1987, Jan-15, Volume: 45, Issue:2 Topics: Adolescent; Adult; Aged; Blood Coagulation; Blood Platelet Disorders; Child; Deamino Arginine Vasopr	1987